Comparative Analysis of Cytokine Levels in Multiple Myeloma Patients: Implications for Natural Killer Cells and Therapeutic Monoclonal Antibodies
Loading...
Date
2024-04
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
University of New Brunswick
Abstract
Multiple myeloma (MM) is a lethal cancer affecting bone marrow (BM) plasma cells, with dysregulated natural killer (NK) cells and cytokine production contributing to disease progression. Monoclonal antibody therapies (mAbs) can induce NK cell responses against tumours, which can potentially be enhanced by cytokine manipulation. This study evaluates cytokine levels in MM patients’ blood compared to the blood of healthy controls (CTR) and the BM of MM patients to assess their potential as therapeutic targets. Using Bio-Plex profiling, eight cytokines (IL-2, IL-8, IL-10, IL-12, IL-15, IL-18, IFN-γ, and TGF-β1) were quantified. Significant differences in cytokine profiles were observed between MM patients and CTR, as well as between MM patients' blood and BM. These findings underscore cytokines’ potential role in MM progression, emphasizing them as potential therapeutic targets. The study lays the groundwork for future research aimed at modulating the cytokine network in MM to augment NK cell responsiveness to mAbs.